Individuals with high level of Lp(a) (> 30.23 mg/dL) and total cholesterol (> 5.35 mmol/L), LDL-C (> 3.36 mmol/L) or non-HDL-C (> 4.38 mmol/L) may warrant aggressive lipid lowing therapy especially for those with type 2 diabetes. The gene discussed is LPA; the disease is type 2 diabetes mellitus.